Compare AGIO & TOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGIO | TOP |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2013 | 2021 |
| Metric | AGIO | TOP |
|---|---|---|
| Price | $37.22 | $16.09 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $46.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 125.7K |
| Earning Date | 11-05-2026 | 07-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | $4,723,765.00 |
| Revenue This Year | $229.47 | N/A |
| Revenue Next Year | $94.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 41.89 |
| 52 Week Low | $22.24 | $1.85 |
| 52 Week High | $46.00 | $17.42 |
| Indicator | AGIO | TOP |
|---|---|---|
| Relative Strength Index (RSI) | 67.97 | 60.16 |
| Support Level | $32.17 | $14.44 |
| Resistance Level | $44.09 | $16.20 |
| Average True Range (ATR) | 1.34 | 1.13 |
| MACD | 0.66 | -0.03 |
| Stochastic Oscillator | 98.33 | 99.69 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.